1. Home
  2. AM vs IMVT Comparison

AM vs IMVT Comparison

Compare AM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antero Midstream Corporation

AM

Antero Midstream Corporation

SELL

Current Price

$19.79

Market Cap

9.7B

Sector

Utilities

ML Signal

SELL

Logo Immunovant Inc.

IMVT

Immunovant Inc.

SELL

Current Price

$29.46

Market Cap

8.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AM
IMVT
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
8.5B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
AM
IMVT
Price
$19.79
$29.46
Analyst Decision
Hold
Buy
Analyst Count
8
17
Target Price
$24.00
★ $48.88
AVG Volume (30 Days)
★ 2.7M
1.3M
Earning Date
10-28-2026
11-09-2026
Dividend Yield
★ 4.30%
N/A
EPS Growth
★ 3.61
N/A
EPS
★ 1.31
N/A
Revenue
★ $1,188,426,000.00
N/A
Revenue This Year
$6.48
N/A
Revenue Next Year
$8.66
N/A
P/E Ratio
$16.00
★ N/A
Revenue Growth
★ 7.43
N/A
52 Week Low
$17.12
$21.43
52 Week High
$23.84
$45.42

Technical Indicators

Market Signals
Indicator
AM
IMVT
Relative Strength Index (RSI) 49.39 40.73
Support Level $20.86 $26.01
Resistance Level $21.84 $29.83
Average True Range (ATR) 0.61 1.07
MACD 0.08 0.40
Stochastic Oscillator 57.58 71.35

Price Performance

Historical Comparison
AM
IMVT

About AM Antero Midstream Corporation

Antero Midstream Corp is a midstream company that owns, operates, and develops midstream energy assets that service Antero Resources' production and completion activity in the Appalachian Basin, located in West Virginia and Ohio. The company has two operating segments: the Gathering and Processing segment, which includes a network of gathering pipelines and compressor stations that collect and process production from Antero Resources wells in West Virginia and Ohio, and the Water Handling segment, which includes two independent systems that deliver water from sources including the Ohio River, local reservoirs, and several regional waterways. The company derives a majority of its revenue from the Gathering and Processing segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: